ArticleApplied biochemistry and biotechnology2026
Prognostic Significance and Immune Landscape of Migrasome-Related Genes in Pancreatic Cancer.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is characterized by early metastasis and high aggressiveness, highlighting the need for novel molecular biomarkers to improve prognostic assessment and therapeutic strategies. In this study, we constructed a migrasome-related prognostic model through multiple cohorts using 101 machine learning algorithms, and applied Shapley Additive Explanations (SHAP) to interpret the model's feature contributions. Six key genes - tetraspanin 5 (TSPAN5), bone morphogenetic protein 1 (BMP1), integrin subunit alpha 3 (ITGA3), integrin subunit alpha 5 (ITGA5), Wnt family member 11 (WNT11), and tetraspanin 2 (TSPAN2) -were identified, mainly enriched in extracellular matrix (ECM)-receptor interaction and cell adhesion pathways. Further analyses showed that these genes were preferentially expressed in tumor cells and fibroblasts, and were associated with an altered immune microenvironment. Drug sensitivity prediction and molecular docking indicated that the monocarboxylate transporter 1 (MCT1) inhibitor AZD-3965 may have therapeutic potential in this context. In general, our findings suggest that migrasome-related genes may contribute to prognostic stratification of pancreatic cancer and point to mechanisms of stroma-immune crosstalk, thereby offering exploratory avenues for personalized treatment.
Indexed as
Identifiers
41801554What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.